查詢結果分析
相關文獻
- Pharmacoeconomic Evaluation of Paliperidone Exended Release versus Olanzapine or Quetiapine in the Treatment for Patients with Schizophrenia in Taiwan
- Metabolic Effects of Paliperidone in a Patient with Schizophrenia
- 照護一位服用抗精神病藥物致體重過重患者之護理經驗
- 藥品介紹:Risperidone長效針劑
- Quetiapine (Seroquel XR)--長效型非典型抗精神病用藥
- 精神科病例討論
- 精神分裂症與治療藥物
- 神經影像學、多巴胺D2受體及抗精神病藥物
- 精神分裂症與雙極型情感疾患之居家照顧需求與家屬之負荷
- 精神分裂症電痙攣治療效應之預測因子
頁籤選單縮合
題名 | Pharmacoeconomic Evaluation of Paliperidone Exended Release versus Olanzapine or Quetiapine in the Treatment for Patients with Schizophrenia in Taiwan=Paliperidone持續性藥效錠相對於口服olanzapine或口服quetiapine用於治療臺灣精神分裂症病人之藥物經濟評估 |
---|---|
作 者 | 蒲若芳; 劉嘉逸; 柯昇穎; 蔡依靜; 楊延光; | 書刊名 | Taiwanese Journal of Psychiatry |
卷期 | 24:4 2010.12[民99.12] |
頁次 | 頁280-290+327 |
分類號 | 418.21 |
關鍵詞 | 精神分裂症; 第二代抗精神病藥物; 成本效益; Schizophrenia; Second-generation antipsychotics; Cost-effectiveness; |
語文 | 英文(English) |
英文摘要 | Objective: This study is to evaluate the cost-effectiveness of oral paliperidone extended-release (ER) compared to two other commonly prescribed oral second-generation antipsychotics (SGAs), olanzapine and quetiapine, in treating patients with schizophrenia in Taiwan. Methods: We developed two decision analytic models (an acute and a long-term treatment model) to predict six-week and one-year health outcomes as well as total medical expenditure. In those models, we considered medication discontinuation rates, response rates, and relapse rates as well as resource use (frequency and unit costs) of regular follow-up, relapse, and adverse effect management. We did a systematic literature review, analysis of the National Health Insurance Research Database, and collection of experts' opinions to obtain the best estimates for model parameters. Health outcome measures were the number of responding patients at six weeks and the number of stable days per patient during a one-year period. We estimated total direct medical costs, and did sensitivity analyses. Results: Among quetiapine, paliperidone ER, and olanzapine, quetiapine was found in this study to have the highest cost and lowest effectiveness. A higher percentage of patients receiving paliperidone ER was found to respond at the end of the six-week period, with a incremental cost-effectiveness ratio (ICER) of NT$10,700 (per patient who responded) compared with olanzapine (US$1=NT$30.5). After a one-year treatment period, paliperidone ER was found to be associated with a higher proportion of patients continuing initial treatment with more number of stable days. The ICER of paliperidone ER compared to that of olanzapine was NT$400 per stable day. Conclusion: Paliperidone ER is a cost-effective alternative to olanzapine or quetiapine for treating patients with schizophrenia in Taiwan. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。